The aim: To study the dynamics of markers of angiogenesis based on insulin-like growth factor-1 (IGF-1) and endostatin, as well as to determine 6-month survival in patients taking zofenopril from the first day of AMI with and without obesity. Materials and methods: using enzyme immunoassay, we determined the level of endostatin and IGF-1 in serum on days 1 and 12 in patients with AMI with the presence and absence of obesity, and a statistical processing of the data obtained. Results: The relationship between obesity and angiogenesis indicators, both activators and inhibitors, was determined, and a significant relationship was found between zofenopril therapy and angiogenesis activator IGF-1. Differences in the survival of patients with complicated AMI were determined depending on the choice of ACE inhibitor in favor of a higher survival rate of patients who took zofenopril. Conclusions: patients who underwent complicated AMI, taking zofenopril, have a higher survival rate during the 6-month follow-up period. Zofenopril stimulated angiogenesis in the examined patients, which was expressed in patients with and without obesity.
Objective: To investigate the association of RDW and VTE including deep vein thrombosis (DVT) and pulmonary embolism (PE) and related mortality.Methods: Major medical databases were systematically searched for observational studies which assessed the association of RDW and VTE published until May 2022. The databases were searched with predefined protocol without language restriction based on PRISMA guidelines. The analysis was performed in RevMan 5.3 to provide pooled measures for Risk Ratio (RR) and weighted mean difference (WMD).Results: Twenty-three studies were enrolled including 6,737 cases and 58,831 controls. Higher RDW was indicated as independent predictors for VTE compared to lower RDW (RR = 1.82, p < 0.00001), comprising DVT and PE (RR = 1.6, p < 0.00001, and RR = 2.05, p = 0.002, respectively). There was also an association between higher RDW and risk of mortality after PE episode with RR = 1.4 (p = 0.0004), involving short-(30-day) and long-term (> 1 year) mortality (RR = 1.79, p = 0.04, and RR = 1.15,p = 0.03, respectively). Compared to lower RDW, higher RDW also revealed a significant association with unprovoked VTE (RR = 2.18, p = 0.02). VTE-group had a higher mean of RDW compared to control with WMD = 1.13% (p < 0.00001), consisting of PE-group (WMD = 0.99%, p < 0.00001) and DVT-group (WMD = 1.07%, p < 0.00001). Among PE patients, The PE-related mortality group also had a higher mean of RDW in comparison to the survivor group with WMD = 1.97%, (p < 0.00001). Conclusions:Higher RDW value was associated with the occurrence of VTE, including DVT, PE, unprovoked VTE, and PE-related mortality. Therefore, the use of the potential role of RDW should be emphasized since it is low-cost and simple to obtain, even in a low-resource setting.
Вступ. Гострий інфаркт міокарда (ГІМ) призводить до складних змін структури ушкодженого та інтактного міокарда. Розширення лівого шлуночка і стоншення ушкодженої тканини є найбільш значущими структурними змінами, що підвищують ризик ускладнень. Одним із провідних механізмів загоєння у хворих на ГІМ є зміна обміну речовин та інтенсивність анґіоґенезу, що сприяє ремоделюванню міокарда лівого шлуночка. За наявності ожиріння порушується метаболізм, зокрема, настає гіперліпідемія, виникають цукровий діабет і гіпертонія, а також інші ураження серцево-судинної системи [1]. Методи лікування, що їх застосовують сьогодні, не дають стійкої втрати маси тіла, а це робить важливим виявлення й управління метаболічними наслідками ожиріння і, таким чином, запобігання виникненню серцево-судинних хвороб [13]. Реґулятори метаболічних процесів із безпосереднім впливом на різні тканини й орґани включають інсуліноподібний фактор росту-1 (ІФР-1), пептидний гормон, який нагадує структуру інсуліну й бере активну участь у анаболічних процесах у сполучній тканині, м'язах, серці. Левова частка ІФР-1 синтезується у клітинах печінки. Але є й інші типи клітин, які також здатні продукувати ІФР-1, зокрема, кардіоміоцити й ендотеліоцити. Рецепторів для ІФР-1 у судинному ендотелії більше, ніж для рецепторів інсуліну. На відміну від інсуліну, який не продукується у тканинах серцево-судинної системи, локальна секреція ІФР-1 відбувається за допомогою автокринних або паракринних механізмів. У дослідженнях in vitro введення ІФР-1 трансґенним мишам фіксували проліферацію клітин гладеньких м'язів та інгібування апоптозу, що викликало стабілізацію атеросклеротичної
Over the last many years, cardiovascular disease has reached epidemic proportions among chronic noncommunicable diseases worldwide. According to the latest tendencies, cardiovascular diseases play the leading role in the formation of current negative health and demographic trends in Ukraine and all over the world: they significantly affect the main health indicators: morbidity, mortality, disability, life expectancy and quality of life. If we take the last 20 years, we can see that the prevalence of CVDs among the Ukrainian population has tripled, and the mortality rate from them has risen by 40%. Review was analysed serum level insulin-like growth factor-I (IGF-I) in patients with acute myocardial infarction and his role in left ventricular remodelling was established. The scientific data regarding the neurohumoral component of acute myocardial infarction pathogenesis have been expanded by increasing levels of the angiogenesis marker IGF-I, which can be explained by his properties as markers of the acute phase of inflammation. An analysis of the relationship between troponin I and IGF-I, a marker of myocardial damage, showed a direct relationship, indicating an increase in troponin I concentration with rising serum IGF-I levels. This indicates that the activity of the angiogenesis marker IGF-I may be associated with the severity and depth of myocardial damage.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.